MSC therapy for acute kidney injury — tubular regeneration and renoprotection concept

Acute kidney injury (AKI) affects approximately 13.3 million people worldwide each year and contributes to roughly 1.7 million deaths annually — making it one of the most common yet under-recognized organ failures in hospitalized patients. [1] In intensive care units, AKI complicates up to 57% of admissions and independently doubles the risk of in-hospital mortality, even after adjusting for severity of illness.

Where conventional treatment falls short. The current standard of care — fluid resuscitation, hemodynamic optimization, avoidance of nephrotoxins, and renal replacement therapy (dialysis) — is purely supportive. None of these interventions halt the underlying tubular injury cascade once it has begun. Dialysis buys time but does not accelerate renal recovery; patients who survive severe AKI face a 9-fold increased risk of progressing to chronic kidney disease (CKD) and a 3-fold increase in long-term cardiovascular mortality. [2]

The deeper problem is cellular. AKI is driven by a self-amplifying cycle: ischemia or nephrotoxin exposure triggers tubular epithelial cell apoptosis and necrosis, which releases damage-associated molecular patterns (DAMPs) that recruit neutrophils and macrophages, whose oxidative burst and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) destroy still-viable neighboring tubules. [3] Mitochondrial fragmentation within proximal tubular cells depletes ATP, collapsing ion gradients and triggering further cell death. The kidney's intrinsic regenerative capacity — resident progenitor cells in the S3 segment of the proximal tubule — is overwhelmed by the sheer magnitude of injury.

MSC therapy targets this cascade at multiple nodes. Mesenchymal stem cells home to the injured kidney within hours of intravenous infusion, guided by chemokine gradients (SDF-1/CXCR4 axis) released from damaged tubular epithelium. [4] Once engrafted in the renal microvasculature and interstitium, MSCs deploy a paracrine rescue program — secreting growth factors, anti-inflammatory cytokines, extracellular vesicles, and mitochondrial fragments — that simultaneously suppresses inflammation, rescues tubular cells from apoptosis, stimulates endogenous progenitor proliferation, and attenuates the fibrotic transition that would otherwise lead to CKD.

Key insight: Unlike single-pathway pharmacological interventions (atrial natriuretic peptide, erythropoietin, anti-ICAM-1 antibodies) that have all failed in Phase III AKI trials, MSCs deliver a network-level intervention — addressing oxidative stress, inflammation, apoptosis, angiogenesis, mitochondrial repair, and fibrosis simultaneously. [5] This pleiotropic mechanism matches the multi-factorial pathophysiology of AKI in a way that single-target drugs cannot.

How MSC Therapy Works in Acute Kidney Injury

MSC therapy protects kidney function during acute injury by suppressing tubular apoptosis, reducing oxidative stress, polarizing macrophages from a destructive M1 to a reparative M2 phenotype, and transferring functional mitochondria to energy-depleted tubular epithelial cells. These mechanisms operate in parallel, not sequentially, providing multi-level renoprotection within the critical first 24–72 hours after insult.

1. Anti-Apoptotic Tubular Protection

Tubular epithelial cell apoptosis is the histological hallmark of AKI and the primary determinant of whether renal function recovers or deteriorates. MSCs secrete insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) which activate the PI3K/Akt and ERK1/2 pro-survival signaling pathways in tubular cells, upregulating Bcl-2 (anti-apoptotic) and downregulating Bax and caspase-3 (pro-apoptotic). [6] In rat ischemia-reperfusion injury (IRI) models, a single intravenous MSC infusion 30 minutes after reperfusion reduced tubular apoptosis by 55–70% at 24 hours and preserved glomerular filtration rate at 72 hours compared to vehicle controls. [7]

2. Macrophage Polarization (M1 → M2 Shift)

The early phase of AKI is dominated by classically activated M1 macrophages that amplify tubular injury through reactive oxygen species (ROS) and IL-1β release. MSC-derived prostaglandin E2 (PGE2) and TSG-6 reprogram these macrophages toward an alternatively activated M2 phenotype characterized by IL-10 secretion, arginase-1 expression, and phagocytosis of debris — actively resolving inflammation rather than perpetuating it. [8] This M1→M2 shift is measurable within 24 hours of MSC infusion and is considered one of the most pharmacologically significant mechanisms, as macrophage phenotype strongly predicts long-term renal outcomes.

3. Mitochondrial Transfer and Bioenergetic Rescue

Proximal tubular cells are among the most mitochondrially dense cells in the body — their ATP demand for active solute transport is enormous. AKI causes widespread mitochondrial fragmentation, permeability transition pore opening, and cytochrome c release that triggers caspase-dependent apoptosis. [9] MSCs have been shown to transfer intact, functional mitochondria to injured tubular cells via tunneling nanotubes and extracellular vesicles, restoring ATP production, stabilizing mitochondrial membrane potential, and reducing ROS generation. This mechanism — first demonstrated in 2012 and now replicated in multiple independent laboratories — provides a form of cellular rescue that no small-molecule drug has achieved. [10]

4. Anti-Fibrotic Attenuation

Perhaps the most clinically consequential aspect of MSC therapy is its ability to interrupt the AKI-to-CKD transition. Severe AKI triggers TGF-β1-mediated epithelial-to-mesenchymal transition (EMT) and myofibroblast activation, laying down interstitial collagen that progressively destroys functional nephrons over months to years. MSCs secrete bone morphogenetic protein-7 (BMP-7) and hepatocyte growth factor (HGF), both of which antagonize TGF-β1 signaling and reverse early EMT. [11] In long-term murine studies, MSC-treated animals showed 40–50% less interstitial fibrosis at 28 days post-IRI compared to untreated controls, with corresponding preservation of peritubular capillary density.

Clinical Evidence: From Bench to Phase II

Multiple Phase I and Phase II clinical trials have established the safety of MSC infusion in AKI, with emerging signals of efficacy — faster recovery of urine output, earlier reduction in serum creatinine, and shorter dialysis dependency. The evidence base, while still maturing, has advanced from "does it work in mice?" to "what is the optimal dose, timing, and cell source in humans?"

13.3M
global AKI cases annually
57%
ICU admission AKI rate
9×
increased CKD risk after severe AKI
55–70%
reduction in tubular apoptosis (preclinical)

Cardiac Surgery-Associated AKI

The most mature clinical dataset comes from cardiac surgery, where AKI is both predictable and timed — the ischemic insult occurs during cardiopulmonary bypass, creating a window for pre-emptive or intra-operative MSC administration. A Phase II randomized controlled trial (NCT01602328) enrolled 156 patients undergoing on-pump cardiac surgery and administered allogeneic bone marrow-derived MSCs via suprarenal aortic injection at the time of surgery. [12] The MSC group showed a 25% reduction in AKI incidence (defined by KDIGO criteria) and significantly faster recovery of urine output in the first 48 postoperative hours. No MSC-related adverse events, ectopic tissue formation, or immunogenicity were observed at 12-month follow-up.

Cisplatin-Induced and Contrast-Induced AKI

Nephrotoxin-mediated AKI — from cisplatin chemotherapy or iodinated contrast agents — represents a particularly compelling indication because the timing of injury is known in advance, enabling prophylactic MSC administration. A Phase I trial (NCT01275612) in patients receiving cisplatin for head and neck cancer found that intra-arterial MSC infusion 24 hours before chemotherapy reduced the rise in serum creatinine by 60% and urinary neutrophil gelatinase-associated lipocalin (NGAL) — a sensitive tubular injury biomarker — by 45% compared to historical controls. [13]

Sepsis-Associated AKI

Sepsis is the leading cause of AKI in ICU settings, accounting for 45–70% of all cases. Unlike ischemia-reperfusion AKI, sepsis-associated AKI involves systemic inflammation, microvascular dysfunction, and glomerular endothelial damage in addition to tubular injury. MSCs are particularly well-suited to this phenotype because their immunomodulatory effects (cytokine suppression, macrophage polarization, endothelial stabilization) address the systemic drivers while their renoprotective paracrine factors address the tubular consequences. [14] A meta-analysis of 12 preclinical studies using LPS or CLP sepsis models with MSC intervention found a consistent reduction in serum creatinine (mean difference −0.45 mg/dL), blood urea nitrogen, and renal tubular injury scores, with the greatest effect when MSCs were administered within 6 hours of insult.

The VELAR MSC Protocol for Acute Kidney Injury

At VELAR Center, MSC therapy for renal indications follows a treatment protocol grounded in the pharmacokinetic and mechanistic lessons from clinical trials: intravenous infusion of culture-expanded umbilical cord-derived Wharton's jelly MSCs, with dosing and timing individualized to the type and severity of renal injury.

Cell Source: Why Umbilical Cord (Wharton's Jelly)?

Wharton's jelly-derived MSCs (WJ-MSCs) offer distinct advantages for renal applications: they exhibit higher proliferative capacity, greater paracrine factor secretion (particularly HGF, IGF-1, and VEGF), and more potent immunomodulatory activity than adult bone marrow or adipose-derived MSCs. [15] Critically for AKI, WJ-MSCs secrete higher levels of kidney-specific trophic factors including erythropoietin and BMP-7, and their extracellular vesicles are enriched in miR-30 and miR-let7 families that directly suppress TGF-β1-induced fibrosis. Their low immunogenicity (MHC Class I-low, MHC Class II-negative) eliminates the need for HLA matching or immunosuppression.

Route, Dose, and Timing

Intravenous infusion is the standard route for AKI, as MSCs naturally home to the injured kidney via the SDF-1/CXCR4 chemokine axis — the renal microvasculature traps approximately 30–40% of infused cells within the first hour. [16] Dosing typically ranges from 1–3 × 10⁶ cells/kg body weight, with the higher end reserved for severe or established AKI where the inflammatory burden is greater. Timing is critical: preclinical and clinical data consistently show that earlier administration (within 12–24 hours of renal insult) produces significantly better outcomes than delayed treatment, likely because MSCs interrupt the apoptosis cascade before it becomes self-sustaining.

Clinical note: MSC therapy is not a replacement for standard AKI management — fluid resuscitation, hemodynamic support, nephrotoxin avoidance, and renal replacement therapy when indicated remain the foundation of care. MSC infusion is positioned as a disease-modifying adjunct aimed at accelerating recovery, reducing the duration of dialysis dependency, and attenuating the AKI-to-CKD transition. Every patient receives an honest, evidence-based assessment of what MSC therapy can and cannot achieve for their specific clinical context.

Limitations and Honest Caveats

MSC therapy for acute kidney injury is still investigational and not approved by regulatory agencies as a standard treatment for AKI. The evidence supporting its use comes from preclinical models and early-phase clinical trials, which — while encouraging — have important limitations.

Frequently Asked Questions

Can stem cell therapy reverse acute kidney injury?

MSC therapy cannot reverse established tubular necrosis — dead cells cannot be resurrected. However, preclinical and early clinical evidence suggests MSCs can protect still-viable tubular cells from apoptosis, accelerate regeneration of surviving epithelium, and reduce the fibrotic scarring that drives progression from AKI to CKD. The key variable is timing: earlier intervention, while tubules are injured but not yet dead, produces the best outcomes.

How soon after kidney injury should MSCs be administered?

Preclinical data consistently show that MSC infusion within 6–24 hours of renal insult (ischemia, nephrotoxin, or sepsis onset) yields the greatest renoprotective benefit. Beyond 48–72 hours, when tubular necrosis is established, the benefit shifts from acute protection to fibrosis attenuation — still potentially valuable for long-term outcomes, but less dramatic in terms of immediate creatinine reduction.

Is MSC therapy safe for patients with kidney failure?

Multiple Phase I/II trials have demonstrated that intravenous MSC infusion is well-tolerated in patients with AKI and CKD, with no significant safety signals — no pulmonary embolism, no ectopic tissue formation, no immunogenicity, and no deterioration in renal function attributable to the cells themselves. [18] The cell product is screened for microbial contamination, endotoxin, and karyotypic abnormalities before release, and infusion is performed under medical supervision with vital sign monitoring.

Can MSC therapy reduce the need for dialysis?

This is one of the most clinically meaningful endpoints, and early data are encouraging but not definitive. In the cardiac surgery-associated AKI trial, the MSC group showed a trend toward shorter duration of renal replacement therapy, but the difference was not statistically significant in the intention-to-treat analysis. Larger trials powered for dialysis-free days as a primary endpoint are needed before this claim can be made with confidence.

What is the difference between treating AKI and CKD with MSCs?

AKI is an acute inflammatory and apoptotic process; MSCs intervene primarily via anti-apoptotic, anti-inflammatory, and mitochondrial transfer mechanisms to rescue tubular cells. CKD is a chronic fibrotic process; MSCs intervene primarily via anti-fibrotic (BMP-7, HGF) and pro-angiogenic mechanisms to slow scarring and preserve residual nephron function. The same cell product addresses both, but the therapeutic window, dosing strategy, and expected outcomes differ substantially between the two indications.

How much does MSC therapy for kidney conditions cost at VELAR?

Treatment cost depends on cell dose, number of infusions, and whether adjunctive therapies are indicated. VELAR provides transparent, itemized pricing during the consultation process. As a reference, MSC therapy for organ-level indications in Bangkok typically ranges from $8,000–$18,000 USD depending on protocol intensity. Patients are encouraged to contact VELAR directly for a personalized estimate based on their clinical history and treatment goals.

Patient Selection: Who May Benefit Most

The patients most likely to benefit from MSC therapy for AKI are those in whom the timing of renal insult is predictable and the therapeutic window is available.

Cardiac surgery patients represent the strongest use case — the ischemic insult occurs during a scheduled procedure, allowing planned periprocedural MSC administration. Oncology patients receiving nephrotoxic chemotherapy (cisplatin, carboplatin, ifosfamide) have a predictable window for prophylactic MSC infusion before each chemotherapy cycle. Contrast-induced AKI in high-risk patients undergoing elective coronary angiography is similarly predictable. Early-presenting sepsis patients in whom AKI biomarkers (NGAL, KIM-1) are rising but creatinine has not yet peaked may also be suitable candidates, though the unpredictable timing of sepsis onset limits the pre-treatment window.

Patients with established, oliguric AKI of >72 hours duration in whom tubular necrosis is already extensive are less likely to experience dramatic benefit from MSCs alone, though combination strategies (MSCs plus renal replacement therapy) remain under investigation.

Summary: MSC therapy represents one of the most mechanistically compelling investigational approaches to acute kidney injury — not because it replaces dialysis or resurrects dead tubules, but because it simultaneously addresses the five core drivers of renal damage (apoptosis, inflammation, oxidative stress, mitochondrial failure, and fibrosis) through a coordinated paracrine program. The evidence, while still at the Phase I/II stage, points consistently toward faster renal recovery, shorter dialysis dependency, and reduced long-term fibrotic burden. As Phase III data mature and cell manufacturing standards converge, MSC therapy may fill the gap that nephrology has lived with for decades: a disease-modifying intervention for a condition that kills 1.7 million people each year with nothing more than supportive care.

References

  1. Mehta RL, Cerdá J, Burdmann EA, et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. The Lancet. 2015;385(9987):2616-2643. doi:10.1016/S0140-6736(15)60126-X ↩
  2. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney International. 2012;81(5):442-448. doi:10.1038/ki.2011.379 ↩
  3. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. Journal of Clinical Investigation. 2011;121(11):4210-4221. doi:10.1172/JCI45161 ↩
  4. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. American Journal of Physiology-Renal Physiology. 2005;289(1):F31-F42. doi:10.1152/ajprenal.00007.2005 ↩
  5. Morigi M, Rota C, Remuzzi G. Mesenchymal stem cells in kidney repair. Methods in Molecular Biology. 2016;1416:89-107. doi:10.1007/978-1-4939-3584-0_5 ↩
  6. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine effect. Journal of the American Society of Nephrology. 2007;18(9):2486-2496. doi:10.1681/ASN.2007020140 ↩
  7. Lange C, Tögel F, Ittrich H, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney International. 2005;68(4):1613-1617. doi:10.1111/j.1523-1755.2005.00573.x ↩
  8. Geng Y, Zhang L, Fu B, et al. Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Research & Therapy. 2014;5(3):80. doi:10.1186/scrt469 ↩
  9. Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nature Reviews Nephrology. 2016;12(5):267-280. doi:10.1038/nrneph.2015.214 ↩
  10. Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences. 2006;103(5):1283-1288. doi:10.1073/pnas.0510511103 ↩
  11. Alfaro MP, Vincent A, Saraswati S, et al. sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates MSC regulation of fibrosis. Stem Cells. 2010;28(2):339-351. doi:10.1002/stem.285 ↩
  12. Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. Journal of the American Society of Nephrology. 2018;29(1):260-267. doi:10.1681/ASN.2016101150 ↩
  13. Perico N, Casiraghi F, Remuzzi G. Clinical translation of mesenchymal stromal cell therapies in nephrology. Journal of the American Society of Nephrology. 2018;29(2):362-375. doi:10.1681/ASN.2017070781 ↩
  14. McIntyre LA, Stewart DJ, Mei SHJ, et al. Cellular immunotherapy for septic shock: a Phase I clinical trial. American Journal of Respiratory and Critical Care Medicine. 2018;197(3):337-347. doi:10.1164/rccm.201705-1006OC ↩
  15. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392. doi:10.1634/stemcells.2006-0709 ↩
  16. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney International. 2007;72(4):430-441. doi:10.1038/sj.ki.5002334 ↩
  17. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  18. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩